Interleukin Genetics To Host Third Quarter 2006 Financial Results Conference Call On November 8
INTERLEUKIN GENETICS TO HOST THIRD QUARTER 2006 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8
– Conference Call Scheduled for 4:30 PM EST – November 8, 2006 –
WALTHAM, MA – November 3, 2006 – Interleukin Genetics, Inc. (AMEX: ILI) today announced that it will release its third quarter financial results on Wednesday, November 8 after the market closes. The Company’s management will host the conference call at 4:30 PM EST to review Interleukin’s financial results and provide a general Company update.
Conference Call Details
To access the live call on November 8, 2006 at 4:30 PM EST, dial (800) 819-9193 (domestic) or (913) 981-4911 (international). The call will also be available live via webcast at www.ilgenetics.com.
Replay access of the teleconference will be available for two weeks following the call by calling (719) 457-0820 (domestic) or (888) 203-1112 (international). The passcode for the replay is 5825472. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing, acquiring, and commercializing personalized health products. The Company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, and nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, Interleukin’s Alan James Group subsidiary sells nutraceutical brands, including Ginkoba™, Ginsana™, and Venastat™ through the nation’s largest food, drug and mass retailers. Interleukin’s current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeutical™ products for distribution through the Alan James Group. Interleukin expects that these programs will also lead to the personalized selection of nutritional and therapeutic products, and provide consumers and healthcare professionals with better preventative product alternatives. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700
11/06/2006